Clinical Trials Logo
  1. Home
  2. Encephalitis
  3. NCT02526550

Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX

Encephalitis Clinical Trial

Official title:
Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children

Clinical Trial Summary

This study was undertaken to assess the immunogenicity and safety of a booster dose of JE-CV after primary vaccination with SA14-14-2 in Thai children aged 1 to <5 years. In addition, to assess the impact of the duration interval after primary vaccination on subsequent booster response.

Clinical Trial Description

The subject will receive one booster dose of IMOJEV with hepatitis A vaccine (inactivated vaccine of GSK) as concomitant vaccine. Blood samples will be collected to assess for Japanese Encephalitis Neutralizing Antibody at baseline (pre-vaccination) and 4 week post -vaccination. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02526550
Study type Interventional
Source Siriraj Hospital
Contact
Status Completed
Phase Phase 4
Start date June 2014
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
Completed NCT00381433 - Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid Phase 1
Completed NCT00031486 - Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir Phase 3
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Completed NCT02906631 - Epidemiology and Prognosis of Encephalitis in Intensive Care
Completed NCT02367664 - A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Terminated NCT00927953 - Treatment of West Nile Virus With MGAWN1 Phase 2
Recruiting NCT05393492 - Regulating Emotions and Behaviors After Brain Injury N/A
Terminated NCT04361344 - Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection N/A
Recruiting NCT04460599 - Neurological Features During COVID19
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Completed NCT02714959 - IL-2 in Refractory Autoimmune Encephalitis Phase 1/Phase 2
Completed NCT01092507 - A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Phase 3
Completed NCT01041573 - Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Phase 3
Not yet recruiting NCT04722328 - Establishment of Prevention and Control System of Central Nervous System Infection
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting NCT06368648 - CoMind Early Feasibility Study
Completed NCT01694524 - Nervous System Infections Among Patients With Febrile Seizure N/A
Completed NCT04080921 - Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis Phase 1/Phase 2